Ban Adil Al-Kaaby
Objectives: to work out the efficacy of (Sofosbuvir/ledipasvir) in treating children with HCV infection. Patients and methods: Patients with positive HCV PCR, aged 7 to 18 years were enrolled. History and clinical examinations and investigations were conducted. HCV genotyping was done (if affordable). Sofosbuvir was given to all or any patients once daily. Ribavirin was added for INF-experienced patients or with established cirrhosis. Follow up with liver function and renal function and PCR was done at 12 weeks (end of treatment); then after 12 weeks post treatment (SVR12). Total duration of therapy was 12 weeks. Extended to 24 in cases with established cirrhosis. trojan horse SPSS version 20 was used for data analysis. Results: the quantity of patients were 22, with mean age of 12.5 years, 14 boys (63.6%), and eight girls (36.4%). Genotype 1 was the dominant type (75%). SVR 12 was achieved in 20 patients (90.9%), the remaining 2 (9.1%) had partial virological response. HBV co-infection was found in 5 cases; they were kept on Entecavir during the course of treatment. All achieved SVR12 for HCV and reduce titter for HBV. Even INF-experienced patients (7 patients 31.8%) were responsive with SVR12. The treatment was well tolerated. Conclusion: Sofosbuvir/ledipasvir is effective in treating HCV in children, and is well tolerated. Key word: Direct acting antivirals, hepatitis C virus, Sofosbuvir/ledipasvir, Pediatrics, children.
PDFShare this article
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
